The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Safety and efficacy of hydrothermal duodenal mucosal resurfacing in patients with type 2 diabetes: the randomised, double-blind, sham-controlled, multicentre REVITA-2 feasibility trial
Open accessAbstract
Objective: Hydrothermal duodenal mucosal resurfacing (DMR) is a safe, outpatient endoscopic procedure. REVITA-2, a double-blind, superiority randomised controlled trial, investigates safety and efficacy of DMR using the single catheter Revita system (Revita DMR (catheter and system)), on glycaemic control and liver fat content in type 2 diabetes (T2D). Design: Eligible patients (haemoglobin A1c (HbA1c) 59–86 mmol/mol, body mass index≥24 and ≤40 kg/m 2 , fasting insulin >48.6 pmol/L, ≥1 oral antidiabetic medication) enrolled in Europe and Brazil. Primary endpoints were safety, change from baseline in HbA1c at 24 weeks, and liver MRI proton-density fat fraction (MRI-PDFF) at 12 weeks. Results: Overall mITT (DMR n=56; sham n=52), 24 weeks post DMR, median (IQR) HbA1c change was −10.4 (18.6) mmol/mol in DMR group versus −7.1 (16.4) mmol/mol in sham group (p=0.147). In patients with baseline liver MRI-PDFF >5% (DMR n=48; sham n=43), 12-week post-DMR liver-fat change was −5.4 (5.6)% in DMR group versus −2.9 (6.2)% in sham group (p=0.096). Results from prespecified interaction testing and clinical parameter assessment showed heterogeneity between European (DMR n=39; sham n=37) and Brazilian (DMR n=17; sham n=16) populations (p=0.063); therefore, results were stratified by region. In European mITT, 24 weeks post DMR, median (IQR) HbA1c change was –6.6 mmol/mol (17.5 mmol/mol) versus –3.3 mmol/mol (10.9 mmol/mol) post-sham (p=0.033); 12-week post-DMR liver-fat change was –5.4% (6.1%) versus –2.2% (4.3%) post-sham (p=0.035). Brazilian mITT results trended towards DMR benefit in HbA1c, but not liver fat, in context of a large sham effect. In overall PP, patients with high baseline fasting plasma glucose ((FPG)≥10 mmol/L) had significantly greater reductions in HbA1c post-DMR versus sham (p=0.002). Most adverse events were mild and transient. Conclusions: DMR is safe and exerts beneficial disease-modifying metabolic effects in T2D with or without non-alcoholic liver disease, particularly in patients with high FPG. Trial registration number: NCT02879383
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The REVITA-2 study assessed liver fat using the MRI-proton density fat fraction (MRI-PDFF) and found a significant reduction in liver fat content three months post-DMR in patients with NAFLD, compared to sham procedures [93].”
From Impact of Bariatric Surgery and Endoscopic Therapies on Liver Health in Metabolic Dysfunction-Associated Steatotic Liver Disease: A Review (2025) · cites this paper as [93]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Matthews, D. R., Hosker, J. P., Rudenski, A. S., Naylor, B. A., Treacher, D. F., & Turner, R. C. (1985) · Diabetologia · doi:10.1007/bf00280883 · Cited by 31,502
Toprak, O., Kurt, H., Sarı, Y., Şarkış, C., Us, H., & Kırık, A. (2017) · Kidney and Blood Pressure Research · doi:10.1159/000468530 · Cited by 29,627
Younossi, Z. M., Koenig, A. B., Abdelatif, D., Fazel, Y., Henry, L., & Wymer, M. (2016) · Hepatology · doi:10.1002/hep.28431 · Cited by 10,781
Matsuda, M., & DeFronzo, R. A. (1999) · Diabetes Care · doi:10.2337/diacare.22.9.1462 · Cited by 5,621
EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease
(2016) · Journal of Hepatology · doi:10.1016/j.jhep.2015.11.004 · Cited by 4,836
A sharper Bonferroni procedure for multiple tests of significance
HOCHBERG, Y. (1988) · Biometrika · doi:10.1093/biomet/75.4.800 · Cited by 4,829
Davies, M. J., D’Alessio, D. A., Fradkin, J., Kernan, W. N., Mathieu, C., Mingrone, G., Rossing, P., Tsapas, A., Wexler, D. J., & Buse, J. B. (2018) · Diabetes Care · doi:10.2337/dci18-0033 · Cited by 3,518
Self-citationYounossi, Z. M., Golabi, P., de Avila, L., Paik, J. M., Srishord, M., Fukui, N., Qiu, Y., Burns, L., Afendy, A., & Nader, F. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.06.021 · Cited by 2,235 · cited 1×
“28 26 Additionally, the European cohort has statistically significant differences between the DMR and sham arms with regards to the number of patients that had a decline of 30% or more in MRI-PDFF from baseline at week 12.”
Hu, F. B. (2011) · Diabetes Care · doi:10.2337/dc11-0442 · Cited by 1,954
Standards of Medical Care in Diabetes—2008
Dora, J. M., Kramer, C. K., & Canani, L. H. (2008) · Diabetes Care · doi:10.2337/dc08-0109 · Cited by 1,409
Cited by
Non-alcoholic fatty liver disease: A patient guideline
Francque, S. M., Marchesini, G., Kautz, A., Walmsley, M., Dorner, R., Lazarus, J. V., Zelber-Sagi, S., Hallsworth, K., Busetto, L., Frühbeck, G., et al. (2021) · JHEP Reports · doi:10.1016/j.jhepr.2021.100322 · Cited by 264
“with the aim of reducing weight and/or improving metabolism (particularly diabetes).(226) Further studies are needed to confirm the efficacy of these techniques and to determine their role in”
BackgroundMolecular and Cellular Mediators of the Gut-Liver Axis in the Progression of Liver Diseases
Bruneau, A., Hundertmark, J., Guillot, A., & Tacke, F. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.725390 · Cited by 97
Jirapinyo, P., Hadefi, A., Huberty, V., Sullivan, S. A., Thompson, C. C., Patai, Á. V., Pannala, R., Goelder, S. K., Kushnir, V. M., Barthet, M. A., et al. (2024) · Endoscopy · doi:10.1055/a-2292-2494 · Cited by 77
Self-citationMASLD treatment—a shift in the paradigm is imminent
Machado, M. V. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2023.1316284 · Cited by 51
Jirapinyo, P., Hadefi, A., Thompson, C. C., Patai, Á. V., Pannala, R., Goelder, S. K., Kushnir, V. M., Barthet, M. A., Apovian, C. M., Boškoski, I., et al. (2024) · Gastrointestinal Endoscopy · doi:10.1016/j.gie.2023.12.004 · Cited by 53
Self-citation
Metadata
- Authors
- Mingrone, G., van Baar, A. C., Devière, J., Hopkins, D., Moura, E., Cercato, C., Rajagopalan, H., Lopez-Talavera, J. C., White, K., Bhambhani, V., Costamagna, G., Haidry, R., Grecco, E., Galvao Neto, M., Aithal, G., Repici, A., Hayee, B., Haji, A., Morris, A. J., Bisschops, R., Chouhan, M. D., Sakai, N. S., Bhatt, D. L., Sanyal, A. J., & Bergman, J. J. G. H. M.
- Affiliations
- Università Cattolica del Sacro Cuore (IT)
- Departments of Gastroenterology and Hepatology, Academic Medical Center Amsterdam, Amsterdam, The Netherlands
- Department of Gastroenterology, Erasme University Hospital, Brussels, Belgium
- Kings Health Partners (GB)
- Universidade de São Paulo (BR)
- Obesity Unit, Department of Endocrinology, Hospital das Clínicas, University of Sao Paulo, Sao Paulo, Brazil
- Fractyl (United States) (US)
- Research and Development, Fractyl Laboratories, Inc, Lexington, Massachusetts, USA
- King's College Hospital (GB)
- Department of Surgery, ABC University, Medical School, São Paulo, Brazil
- University of Nottingham (GB)
- Humanitas University (IT)
- Glasgow Royal Infirmary (GB)
- KU Leuven (BE)
- University College London (GB)
- Brigham and Women's Hospital (US)
- Virginia Commonwealth University (US)
- Amsterdam UMC Location University of Amsterdam (NL)
- Corresponding author
- Mingrone, Geltrude
- ORCID
- Venue
- Gut
- Publisher
- BMJ
- Published
- 2021-02-17
- Volume
- 71
- Issue
- 2
- Pages
- 254-264
- ISSN
- 0017-5749 (ISSN-L)
- 1468-3288
- PMC
- PMC8761999
- OpenAlex
- W3131132851
- Cited by
- 120
- References
- 33
- Citations by year
- 2026: 18 · 2025: 32 · 2024: 32 · 2023: 19 · 2022: 11 · 2021: 8
- FWCI
- 13.05
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Gut (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Repository@Nottingham (University of Nottingham) (acceptedVersion, other-oa)
- Pure Amsterdam UMC (acceptedVersion, cc-by)
- Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles) (submittedVersion, other-oa)
- Lirias (KU Leuven) (submittedVersion, other-oa)
- Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
- UCL Discovery (University College London) (submittedVersion)
- Research Portal (King's College London) (submittedVersion, cc-by-nc)
- Repository@Nottingham (University of Nottingham) (submittedVersion, cc-by-nc)
- PubliCatt (Università Cattolica del Sacro Cuore) (submittedVersion, other-oa)
- Funders
- Fractyl (N/A)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- type 2 diabetes, glycemic control, HbA1c, liver fat, proton density fat fraction, endoscopic treatment, regional heterogeneity, treatment safety, type 2 diabetes remission, insulin resistance, non-alcoholic fatty liver disease
- MeSH terms
- Endoscopic Mucosal Resection, Adult, Aged, Diabetes Mellitus, Type 2, Double-Blind Method, Duodenum, Feasibility Studies, Female, Glycated Hemoglobin, Humans, Hyperthermia, Induced, Intestinal Mucosa, Male, Middle Aged, Treatment Outcome, Catheter Ablation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Safety and efficacy of hydrothermal duodenal mucosal resurfacing in patients with type 2 diabetes: the randomised, double-blind, sham-controlled, multicentre REVITA-2 feasibility trial. https://app.cochat.ai/papers/10.1136/gutjnl-2020-323608
- The paper
- Mingrone, G., van Baar, A. C., Devière, J., Hopkins, D., Moura, E., Cercato, C., Rajagopalan, H., Lopez-Talavera, J. C., White, K., Bhambhani, V., Costamagna, G., Haidry, R., Grecco, E., Galvao Neto, M., Aithal, G., Repici, A., Hayee, B., Haji, A., Morris, A. J., . . . Bergman, J. J. G. H. M. (2022). Safety and efficacy of hydrothermal duodenal mucosal resurfacing in patients with type 2 diabetes: the randomised, double-blind, sham-controlled, multicentre REVITA-2 feasibility trial. Gut. https://doi.org/10.1136/gutjnl-2020-323608
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.